Apparatus for crimping a stent assembly

• US 7,225,518 B2
• Filed: 02/23/2004
• Issued: 06/05/2007
• Est. Priority Date: 02/23/2004
• Status: Expired due to Fees

• Current Assignee: Boston Scientific Scimed, Inc. (Boston Scientific Corporation)
• Original Assignee: Boston Scientific Scimed, Inc. (Boston Scientific Corporation)
• Inventors: Weber, Jan, Eidenschink, Tracee, Jagger, Karl A., Brown, Terry V.
• Primary Examiner(s): Cozart; Jermie E.
• Application Number:
  US10/784,337
• Publication Number:
  US 20050183259A1
• Time in Patent Office: 1,198 Days
• Field of Search: 295/08, 295/15, 295/16, 292/835, 724/02, 606/108, 623/1.11
• US Class Current: 29/283.5
• CPC Class Codes: A61F 2/856 Single tubular stent with a side portal passage
• CPC Class Codes: A61F 2/9522 Means for mounting a stent or stent-graft onto or into a placement instrument
• CPC Class Codes: A61F 2/9526 using a mandrel
• CPC Class Codes: A61F 2/954 for placing stents or stent-grafts in a bifurcation
• CPC Class Codes: A61F 2/958 Inflatable balloons for placing stents or stent-grafts
• CPC Class Codes: A61F 2002/067 modular
• CPC Class Codes: A61M 2025/0058 having an electroactive polymer material, e.g. for steering purposes, for control of flexibility, for locking, for opening or closing
• CPC Class Codes: B25B 27/10 inserting fittings into hoses
• CPC Class Codes: Y10T 29/49913 by constricting outer annulus
• CPC Class Codes: Y10T 29/49925 Inward deformation of aperture or hollow body wall
• CPC Class Codes: Y10T 29/49927 Hollow body is axially joined cup or tube
• CPC Class Codes: Y10T 29/53065 with means to fasten by deformation
• CPC Class Codes: Y10T 29/53996 by deforming

Abstract

A stent assembly comprises a rotatable sheath and a stent. The assembly is crimped or reduced in diameter prior to loading onto a catheter by one or more crimping apparatuses. One crimping apparatus comprises a blade having a stepped configuration. A mandrel may be used to support the assembly during crimping. The mandrel may have an expandable region. A protective sheath may be used to protect the stent during crimping and to redirect the crimping forces to desired locations about the assembly.

Claims

1. A system for reducing the cross-sectional surface area of a stent assembly comprising:

a stent contracting assembly, the stent contracting assembly comprising a plurality of moveable contracting members, each of the contracting members having a predetermined shape, at least one of the contracting members having a different predetermined shape than the predetermined shape of each of the other contracting members, the plurality of contracting members defining a cross-sectional surface area reduction chamber, the chamber having a reduced cross-sectional surface area configuration and a pre-reduction cross-sectional surface area configuration, the contracting assembly constructed and arranged to receive at least a portion of a stent assembly into the chamber, wherein when the chamber is in the pre-reduction cross-sectional surface area configuration the at least a portion of the stent assembly has a first cross-sectional surface area and when the chamber is in the reduced cross-sectional surface area configuration the at least a portion of the stent assembly has a second cross-sectional surface area, the second cross-sectional surface area being less than the first cross-sectional surface area; and

a first mandrel, a portion of the first mandrel constructed and arranged to be positioned within the cross-sectional surface area reduction chamber, a first portion of the stent assembly disposed about the portion of the first mandrel;

a second mandrel, a portion of the second mandrel constructed and arranged to be positioned within the cross-sectional surface area reduction chamber, a second portion of the stent assembly disposed about the portion of the second mandrel.

2. The system of claim 1 wherein the predetermined shape of the contracting members is substantially rectangular.

3. The system of claim 2 wherein a stent assembly engagement surface of the at least one of the contracting members defines a stair-step area.

4. The system of claim 2 wherein a stent assembly engagement surface of the at least one of the contracting members comprises a soft contacting region and a hard contacting region along an axis of the chamber.

5. The system of claim 1 wherein the portion of the first mandrel is expandable from an unexpanded first mandrel diameter to an expanded first mandrel diameter, the expanded first mandrel diameter being greater than the unexpanded first mandrel diameter.

6. The system of claim 5 wherein when the cross-sectional surface area reducing chamber is in the reduced cross-sectional surface area configuration, the first mandrel is positioned within the cross-sectional surface area reducing chamber and the portion of the first mandrel is expanded to the expanded first mandrel diameter.

7. The system of claim 5 wherein when the stent assembly is in the second cross-sectional surface area, the portion of the first mandrel is expanded to the expanded first mandrel diameter.

8. The system of claim 5 wherein the portion of the first mandrel comprises an expandable balloon.

9. The system of claim 5 wherein at least the portion of the first mandrel is at least partially constructed from an electro-active polymer.

10. The system of claim 5 wherein at least the portion of the first mandrel is constructed from one or more layers of the group of layers consisting of:

a conductive layer, a proton exchange layer, a carbon nanotube layer, an elastic layer, and any combination thereof.

11. The system of claim 1 wherein the portion of the second mandrel is expandable from an unexpanded second mandrel diameter to an expanded second mandrel diameter, the expanded second mandrel diameter being greater than the unexpanded second mandrel diameter.

12. The system of claim 11 wherein when the cross-sectional surface area reducing chamber is in the reduced cross-sectional surface area configuration, the second mandrel is positioned within the cross-sectional surface area reducing chamber and the portion of the second mandrel is expanded to the expanded second mandrel diameter.

13. The system of claim 11 wherein when the stent assembly is in the second cross-sectional surface area, the portion of the second mandrel is expanded to the expanded second mandrel diameter.

14. The system of claim 5 wherein at least the portion of the first mandrel is constructed from a plurality of layers, the plurality of layers comprising:

a conductive layer, a proton exchange layer, a carbon nanotube layer and an elastic membrane layer.

15. The system of claim 11 wherein the portion of the second mandrel comprises an expandable balloon.

16. The system of claim 11 wherein at least the portion of the second mandrel is at least partially constructed from an electro-active polymer.

17. The system of claim 11 wherein at least the portion of the second mandrel is constructed from one or more layers of the group of layers consisting of:

a conductive layer, a proton exchange layer, a carbon nanotube layer, an elastic layer, and any combination thereof.

18. The system of claim 11 wherein at least the portion of the second mandrel is constructed from a plurality of layers, the plurality of layers comprising:

a conductive layer, a proton exchange layer, a carbon nanotube layer and an elastic membrane layer.

19. The system of claim 1 further comprising a second stent contracting assembly, the second stent contracting assembly comprising a plurality of moveable contracting members, the plurality of contracting members of the second stent contracting assembly defining a cross-sectional surface area reduction chamber of the second stent contracting assembly, the chamber of the second stent contracting assembly having a reduced cross-sectional surface area configuration and a pre-reduction cross-sectional surface area configuration, the second stent contracting assembly constructed and arranged to receive the stent assembly into the chamber, wherein when the chamber of the second stent contracting assembly is in the pre-reduction cross-sectional surface area configuration, a proximal portion of the stent assembly has a first cross-sectional surface area and when the chamber of the second stent contracting assembly is in the reduced cross-sectional surface area configuration, the proximal portion of the stent assembly has a second cross-sectional surface area, the second cross-sectional surface area being less than the first cross-sectional surface area.

20. The system of claim 19 wherein when the chamber of the second stent contracting assembly is in the pre-reduction cross-sectional surface area configuration or the reduced cross-sectional surface area configuration, the cross-sectional surface area of a distal portion of the stent assembly is substantially the same.

21. A system for reducing the cross-sectional surface area of a stent assembly comprising:

a stent contracting assembly, the stent contracting assembly comprising a plurality of moveable contracting members, each of the contracting members having a predetermined shape, at least one of the contracting members having a different predetermined shape than the predetermined shape of each of the other contracting members, the plurality of contracting members defining a cross-sectional surface area reduction chamber, the chamber having a reduced cross-sectional surface area configuration and a pre-reduction cross-sectional surface area configuration, the contracting assembly constructed and arranged to receive at least a portion of a stent assembly into the chamber, wherein when the chamber is in the pre-reduction cross-sectional surface area configuration the at least a portion of the stent assembly has a first cross-sectional surface area and when the chamber is in the reduced cross-sectional surface area configuration the at least a portion of the stent assembly has a second cross-sectional surface area, the second cross-sectional surface area being less than the first cross-sectional surface area; and

a protective sheath, the protective sheath constructed and arranged to be positioned within the cross-sectional surface area reduction chamber, the protective sheath disposed about the stent assembly;

wherein the protective sheath comprises a wall thickness and an inside surface, the inside surface being defined by a wall thickness pattern, the wall thickness pattern comprising alternating thicker portions of the wall thickness and thinner portions of the wall thickness, the thicker portions extending radially inward toward the stent assembly to a greater extent than the thinner portions, a thinner portion being positioned between each thicker portion.

22. The system of claim 21 wherein the protective sheath further comprises a proximal region and a distal region, the inside surface of the proximal region having a pattern of alternating thicker portions of the wall thickness and thinner portions of the wall thickness that is different than the pattern of the distal region.

23. The system of claim 22 wherein the wall thickness pattern of the proximal region of the inner surface of the protective sheath comprises a thinner portion having a greater circumferential length than each of the other thinner portions.

24. The system of claim 22 wherein the protective sheath is at least partially constructed of urethane.

25. The system of claim 24 wherein the protective sheath is formed by extrusion or injection molding.

26. The system of claim 21 wherein the inside surface of the protective sheath comprises at least one therapeutic agent, the at least one therapeutic agent constructed and arranged to be transferred to the at least a portion of the stent assembly when the chamber is in the reduced cross-sectional surface area configuration.

27. The system of claim 26 wherein the at least one therapeutic agent is at least one non-genetic therapeutic agent selected from at least one member of the group consisting of:

anti-thrombogenic agents, heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone);

anti-proliferative agents, enoxaprin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid;

anti-inflammatory agents, dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine;

antineoplastic/antiproliferative/anti-miotic agents, paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors;

anesthetic agents, lidocaine, bupivacaine and ropivacaine;

anti-coagulants, D-Phe-Pro-Arg chloromethyl keton, an RGD peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides;

vascular cell growth promoters, growth factor inhibitors, growth factor receptor antagonists, transcriptional activators, and translational promoters, vascular cell growth inhibitors, growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin;

bifunctional molecules consisting of an antibody and a cytotoxin;

cholesterol-lowering agents;

vasodilating agents; and

agents which interfere with endogenous vascoactive mechanisms, and any combinations thereof.

28. The system of claim 26 wherein the at least one therapeutic agent is at least one genetic therapeutic agent selected from at least one member of the group consisting of:

anti-sense DNA and RNA;

DNA coding for anti-sense RNA, tRNA or rRNA to replace defective or deficient endogenous molecules;

angiogenic factors including growth factors, acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor .alpha. and .beta., platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor .alpha., hepatocyte growth factor and insulin like growth factor;

cell cycle inhibitors including CD inhibitors, thymidine kinase (“

TK”

) and other agents useful for interfering with cell proliferation;

at least one of the family of bone morphogenic proteins (“

BMP'"'"'s”

), BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Any of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7;

dimeric proteins, homodimers, heterodimers, or combinations thereof, alone or together with other molecules;

molecules capable of inducing an upstream or downstream effect of a BMP, “

hedgehog”

proteins, or the DNA'"'"'s encoding them and any combinations thereof.

29. The system of claim 26 wherein the at least one therapeutic agent is at least one type of cellular material selected from at least one member of the group consisting of:

cells of human origin (autologous or allogeneic);

cells of non-human origin (xenogeneic) and any combination thereof.

30. The system of claim 29 wherein the cellular material is selected from at least one member of the group consisting of:

side population cells;

lineage negative cells;

lineage negative CD34⁻

cells;

lineage negative CD34⁺ cells;

lineage negative ⁻

cKit⁺ cells;

mesenchymal stem cells;

cord blood bells;

cardiac or other tissue derived stem cells;

whole bone marrow;

boner marrow mononuclear cells;

endothelial progenitor cells;

satellite cells;

muscle derived cells;

go cells;

endothelial cells;

adult cardiomyocytes;

fibroblasts;

smooth muscle cells;

cultures of mesenchymal stem cells with 5-aza forces differentiation into cardiomyocytes;

adult cardiac fibroblasts +5-aza;

genetically modified cells;

tissue engineered grafts;

MyoD scar fibroblasts;

Pacing cells;

embryonic stem cell clones;

embryonic stem cells;

fetal or neonatal cells;

immunologically masked cells;

tissue engineered grafts;

genetically modified cells;

teratoma derived cells and any combinations thereof.

31. The system of claim 26 wherein the at least one therapeutic agent comprises at least one polymer coating, the at least one coating selected from at least one member of the group consisting of:

polycarboxylic acids;

cellulosic polymers, including cellulose acetate and cellulose nitrate;

gelatin;

polyvinylpyrrolidone;

cross-linked polyvinylpyrrolidone;

polyanhydrides including maleic anhydride polymers;

polyamides;

polyvinyl alcohols;

copolymers of vinyl monomers, EVA;

polyvinyl ethers;

polyvinyl aromatics;

polyethylene oxides;

glycosaminoglycans;

polysaccharides;

polyesters including polyethylene terephthalate;

polyacrylamides;

polyethers;

polyether sulfone;

polycarbonate;

polyalkylenes including polypropylene, polyethylene and high molecular weight polyethylene;

halogenated polyalkylenes including polytetrafluoroethylene;

polyurethanes;

polyorthoesters;

proteins;

polypeptides;

silicones;

siloxane polymers;

polylactic acid;

polyglycolic acid;

polycaprolactone;

polyhydroxybutyrate valerate and blends and copolymers thereof;

coatings from polymer dispersions, polyurethane dispersions, fibrin, collagen and derivatives thereof;

polysaccharides, celluloses, starches, dextrans, alginates and derivatives;

hyaluronic acid;

squalene emulsions;

polyacrylic acid, a copolymer of polylactic acid and polycaprolactone;

medical-grade biodegradable materials, PGA-TMC, Tyrosine-Derived Polycarbonates and arylates;

polycaprolactone co butyl acrylate and other co polymers;

Poly-L-lactic acid blends with DL-Lactic Acid;

Poly(lactic acid-co-glycolic acid);

polycaprolactone co PLA;

polycaprolactone co butyl acrylate and other copolymers;

Tyrosine-Derived Polycarbonates and arylate;

poly amino acid;

polyphosphazenes;

polyiminocarbonates;

polydimethyltrimethylcarbonates;

biodegradable CA/PO₄'"'"'s;

cyanoacrylate;

50/50 DLPLG;

polydioxanone;

polypropylene fumarate;

polydepsipeptides;

macromolecules, chitosan and Hydroxylpropylmethylcellulose;

surface erodible material;

maleic anhydride copolymers;

zinc-calcium phosphate;

amorphous polyanhydrides;

sugar;

carbohydrate;

gelatin;

biodegradable polymers; and

polymers dissolvable in bodily fluids;

A block copolymers;

B block copolymers and any combinations thereof.

32. A system for reducing the diameter of a stent assembly comprising:

a stent contracting assembly, the stent contracting assembly comprising a plurality of moveable contracting members, the plurality of contracting members defining a diameter reduction chamber, the chamber having a reduced diameter configuration and a pre-reduction diameter configuration, the stent contracting assembly constructed and arranged to receive the stent assembly into the chamber, wherein when the chamber of the stent contracting assembly is in the pre-reduction diameter configuration at least a portion of the stent assembly has a first diameter and when the chamber is in the reduced diameter configuration the at least a portion of the stent assembly has a second diameter, the second diameter being less than the first diameter;

a first mandrel, a portion of the first mandrel constructed and arranged to be positioned within the diameter reduction chamber, a first portion of the stent assembly disposed about the portion of the first mandrel; and

a protective sheath, the protective sheath constructed and arranged to be positioned within the diameter reduction chamber, the protective sheath disposed about the stent assembly, the protective sheath having a wall thickness and an inside surface, the inside surface being defined by a wall thickness pattern, the wall thickness pattern comprising alternating thicker portions of the wall thickness and thinner portions of the wall thickness, the thicker portions extending radially inward toward the stent assembly to a greater extent than the thinner portions, a thinner portion being positioned between each thicker portion.

33. The system of claim 32 further comprising a second mandrel, a portion of the second mandrel constructed and arranged to be positioned within the diameter reduction chamber, a second portion of the stent assembly disposed about the portion of the second mandrel.

34. A system for reducing the cross-sectional surface area of a stent assembly comprising:

a stent contracting assembly, the stent contracting assembly comprising a plurality of moveable contracting members, each of the contracting members having an elongate edge with a predetermined shape, at least one of the contracting members having a different elongate edge predetermined shape than the elongate edge predetermined shape of each of the other contracting members, the elongate edges of the plurality of contracting members defining a contracting chamber, the contracting chamber having a first cross-sectional shape along a portion of a length of the contracting chamber and a second cross-sectional shape along another portion of the length of the contracting chamber, the first cross-sectional shape having a stepped shape area along only a portion of a circumference of the contracting chamber, the contracting assembly constructed and arranged to receive at least a portion of a stent assembly into the chamber.

35. The system of claim 34 wherein the first cross-sectional shape is generally circular and the second cross-sectional shape is generally ellipsoid shaped.

36. The system of claim 34 wherein the elongate edge predetermined shape of the at least one of the contracting members defines a stair-step shape.

37. The system of claim 34 further comprising a first mandrel, a portion of the first mandrel constructed and arranged to be positioned within the reduction chamber, a first portion of the stent assembly disposed about the portion of the first mandrel.

38. The system of claim 37 wherein the portion of the first mandrel is expandable from an unexpanded first mandrel diameter to an expanded first mandrel diameter, the expanded first mandrel diameter being greater than the unexpanded first mandrel diameter.

39. The system of claim 38 further comprising a second mandrel, a portion of the second mandrel constructed and arranged to be positioned within the reduction chamber, a second portion of the stent assembly disposed about the portion of the second mandrel.

40. The system of claim 39 wherein the portion of the second mandrel is expandable from an unexpanded second mandrel diameter to an expanded second mandrel diameter, the expanded second mandrel diameter being greater than the unexpanded second mandrel diameter.

41. The system of claim 39 wherein the portion of the second mandrel comprises an expandable balloon.

42. The system of claim 39 wherein at least the portion of the second mandrel is at least partially constructed from an electro-active polymer.

43. The system of claim 37 wherein the portion of the first mandrel comprises an expandable balloon.

44. The system of claim 37 wherein at least the portion of the first mandrel is at least partially constructed from an electro-active polymer.

45. A system for reducing the cross-sectional surface area of a stent assembly comprising:

a stent contracting assembly, the stent contracting assembly comprising a plurality of moveable contracting members, each of the contracting members having a predetermined shape, at least one of the contracting members having a different predetermined shape than the predetermined shape of each of the other contracting members, the plurality of contracting members defining a cross-sectional surface area reduction chamber, the chamber having a reduced cross-sectional surface area configuration and a pre-reduction cross-sectional surface area configuration, the contracting assembly constructed and arranged to receive at least a portion of a stent assembly into the chamber, wherein when the chamber is in the pre-reduction cross-sectional surface area configuration the at least a portion of the stent assembly has a first cross-sectional surface area and when the chamber is in the reduced cross-sectional surface area configuration the at least a portion of the stent assembly has a second cross-sectional surface area, the second cross-sectional surface area being less than the first cross-sectional surface area;

a first mandrel, a portion of the first mandrel constructed and arranged to be positioned within the cross-sectional surface area reduction chamber, a first portion of the stent assembly disposed about the portion of the first mandrel and

a second stent contracting assembly, the second stent contracting assembly comprising a plurality of moveable contracting members, the plurality of contracting members of the second stent contracting assembly defining a cross-sectional surface area reduction chamber of the second stent contracting assembly, the chamber of the second stent contracting assembly having a reduced cross-sectional surface area configuration and a pre-reduction cross-sectional surface area configuration, the second stent contracting assembly constructed and arranged to receive the stent assembly into the chamber, wherein when the chamber of the second stent contracting assembly is in the pre-reduction cross-sectional surface area configuration, a proximal portion of the stent assembly has a first cross-sectional surface area and when the chamber of the second stent contracting assembly is in the reduced cross-sectional surface area configuration, the proximal portion of the stent assembly has a second cross-sectional surface area, the second cross-sectional surface area being less than the first cross-sectional surface area.

46. The system of claim 45 wherein when the chamber of the second stent contracting assembly is in the pre-reduction cross-sectional surface area configuration or the reduced cross-sectional surface area configuration, the cross-sectional surface area of a distal portion of the stent assembly is substantially the same.